Pharmaceutical Technology

OCTOBER 23, 2023

At ESMO 2023, interim results from the Phase III LITESPARK-005 trial evaluating MSD’s Welireg (belzutifan) as a treatment for patients with previously treated advanced clear cell renal cell carcinoma (RCC) were presented.

Leads 75

Leads Patients 75

pharmaphorum

DECEMBER 22, 2022

The life sciences industry is flexing towards innovation in new areas, faster than ever before, and increasing patient care in astonishing ways. We can now measure patient activity, steps, and movement continuously and in real time, which serves as a new potential indicator of treatment effectiveness.

FDA 97

FDA Patients Electronics Medical 97

PM360

APRIL 18, 2023

ISPOR—The Professional Society for Health Economics and Outcomes Research announced the plenary sessions and speakers for its annual international conference, ISPOR 2023. ISPOR is recognized globally as the leading professional society for health economics and outcomes research and for its role in improving healthcare decisions.

Electronics 97

Electronics Healthcare Healthcare Medicine 97

European Pharmaceutical Review

JANUARY 30, 2023

In its first meeting of 2023, the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) recommended four new medicines for approval, providing positive opinions for two type 2 diabetes drugs. Ultimately, this can lead to a progressive decrease in mobility and other severe impairments.

Side effects 96

Side effects Medicine Marketing Patients 96

LEVO Health

JANUARY 31, 2023

Therefore, it is essential to become familiar with the role SEO strategy plays in healthcare marketing and healthcare SEO best practices that should be employed in 2023 to create a successful digital marketing plan. In turn, this may lead to more patients visiting your website and ultimately booking appointments at your practice.

Healthcare 96

Healthcare Healthcare Marketing Engineering 96

PM360

APRIL 18, 2023

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its ISPOR Real-World Evidence Summit 2023 scheduled for May 7 in Boston, MA, USA. The Summit is collocated with and being held immediately prior to the Society’s annual international conference, ISPOR 2023.

Food and Drug Administration 96

Food and Drug Administration Healthcare Healthcare Food 96

LEVO Health

DECEMBER 20, 2022

As 2023 approaches, there are several strategies you can adopt to improve your healthcare marketing efforts and grow your practice. Adopting the following six marketing strategies may help you stay competitive, bring in new patients, and grow your practice substantially. 6 Medical Marketing Strategies to Adopt in 2023.

Healthcare 98

Healthcare Healthcare Marketing Media 98

European Pharmaceutical Review

NOVEMBER 9, 2023

MANUFACTURING Continuous direct compression: opening up faster access to oral dose medication Deborah McElhone, CPI’s Medicines Manufacturing Innovation Centre IN-DEPTH FOCUS: QA/QC MICROBIOLOGY Bioburden and sterility testing: how to conserve gene therapy product Kathy Zagaroli, Senior Director of Quality Control at Kiniksa Pharmaceuticals Tom Bujold, (..)

Pharmaceutical 98

Pharmaceutical Manufacturing Medicine Management 98

PM360

JULY 13, 2023

PM360 asked experts in helping patients stay on their prescribed therapies about where the industry could make the biggest improvements and how to better detect potential barriers. How can the industry better monitor and detect potential barriers to adherence for individual patients? How can they improve?

Medical 98

Medical Patients Education Transportation 98

European Pharmaceutical Review

MARCH 2, 2023

This article explores some of the most notable developments of 2022, and areas that are likely to be a growing focus for data-driven transformation in 2023. EU Clinical Trial Information System From February 2023 all new clinical trials applications must be submitted via the new portal.

Food and Drug Administration 98

Food and Drug Administration Government Management Medicine 98

Star OUTiCO

NOVEMBER 30, 2022

Reassess ahead of 2023. Q4 is all about company budgets so employers will be looking to get new starters over the line before 2023, which means competing with others and streamlining processes to make sure they secure the talent they’re after. Top 5 most in-demand soft skills for 2022. How to customise your LinkedIn profile url.

Recruitment 98

Recruitment Pharma Leads Training 98

Pharmaceutical Technology

JUNE 8, 2023

The use of 4D Molecular Therapeutics’ (4DMT) aerosolised gene therapy 4D-710 has improved the quality-of-life and spirometry-measured outcomes in three cystic fibrosis patients , based on early results from a Phase I/II study presented at this year’s annual meeting of the European Cystic Fibrosis Society (ECFS).

Patients 98

Patients Food and Drug Administration Food Safety 98

Legacy MEDSearch

DECEMBER 21, 2022

a groundbreaking respiratory support technology company, announced today that it has begun the manufacturing process for the ALICE CPB (Cardiopulmonary Bypass) device (the “ALICE device”) to undergo the Verification and Validation phase prior to its planned 2023 submission to the U.S. and Israel.

Manufacturing 98

Manufacturing FDA Food and Drug Administration Medical 98

Pharmaceutical Technology

JUNE 26, 2024

In this issue: UK’s new Netflix-style funding model for antibiotics, the Swiss biotech ecosystem recuperates from financial instability of 2023, how patient advocacy can lead to more successful clinical trials, and more.

Leads 96

Leads Patients 96

European Pharmaceutical Review

APRIL 10, 2025

Key findings for UK clinical trials For clinical trials submitted between 2019 and 2023, highlights from the analysis showed that one in eight trials tested treatments in humans for the first time. Despite these advances, the analysis found that disparities in representation of patient populations.

Pharmacology 52

Pharmacology Medicine Patients Leads 52

European Pharmaceutical Review

JUNE 5, 2023

Ninety-four percent of advanced stage (3 or 4) classic Hodgkin lymphoma patients treated with nivolumab, a PD-1 checkpoint inhibitor plus AVD chemotherapy (N-AVD) had one-year progression-free survival (PFS), according to Phase III trial results. Then 487 were part of the BV-AVD group.

Patients 98

Patients Side effects Leads Healthcare 98

Legacy MEDSearch

DECEMBER 19, 2022

Chairman, Dave Ferrera, announced treatment of the first patients in North America with the BossStent® device designed to treat patients with symptomatic cerebral venous diseases. Both the EU and FDA clinical trials will be initiated in Q2 2023 for the purpose of obtaining European and US regulatory approvals respectively in Q1 2024.

Patients 98

Patients Recruitment Physicians Management 98

European Pharmaceutical Review

JANUARY 18, 2024

An attractive destination for ATMP clinical trials Based on the Cell and Gene Therapy Catapult (CGT Catapult)’s recently published UK 2023 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database , the UK is an attractive location for ATMP clinical trials. There were 175 ongoing trials in 2023, compared to 178 in 2022.

Manufacturing 111

Manufacturing Distribution Medicine Government 111

PM360

APRIL 7, 2023

Reduced patient out-of-pocket (OOP) costs in Part D have the potential to reduce beneficiary reliance on foundation support, with commensurate reductions in manufacturer donations required. The business-to-business market leaders must find new and creative ways to help patients receive their treatments.

Manufacturing 97

Manufacturing Insurance Marketing Government 97

European Pharmaceutical Review

JUNE 10, 2024

The first industrial-scale pharmaceutical manufacturing facility for production of lead-212-based radioligand therapies has been inaugurated. This news follows the company beginning construction on a similar facility in France , which is set to produce lead-212 radioligand therapies for the European market.

Manufacturing 98

Manufacturing Distribution Leads Pharmaceutical manufacturing 98

Pharmaceutical Technology

JANUARY 10, 2023

“Currently, teplizumab can delay the progression to T1D for people whose immune system has begun attacking their insulin-producing cells, but who don’t yet need insulin to survive,” says Josie Clarkson, Research Communications Lead at JDRF UK. Approximately 30% of patients present after age 18, the FDA says.

Patients 98

Patients FDA Medicine Education 98

Pharmaceutical Technology

APRIL 17, 2023

PRA023, Prometheus’s lead candidate, is a humanised monoclonal antibody (mAb) targeting tumour necrosis factor (TNF)-like ligand 1A (TL1A). The agreement with Prometheus will accelerate our growing presence in immunology where there remains substantial unmet patient need. TL1A is implicated in intestinal inflammation and fibrosis.

Engineering 105

Engineering Medicine Patients Leads 105

European Pharmaceutical Review

MAY 12, 2023

Innovative therapies for rare diseases The acquisition will help to drive the growth of CTI’s lead product, kinase inhibitor VONJO ® (pacritinib) “in treating myeloproliferative disease,” stated Dr Adam Craig, President, Chief Executive Officer and Interim Chief Medical Officer of CTI BioPharma. The post $1.7b

Food and Drug Administration 105

Food and Drug Administration Biopharma Medicine Food 105

European Pharmaceutical Review

OCTOBER 4, 2023

POINT’s lead programmes are currently in late-stage development. It is being investigated for patients with metastatic castration-resistant prostate cancer (mCRPC) after progression on hormonal treatment. Topline data from this study are expected in Q4 of 2023. The treatment is currently being studied in a Phase III trial.

Biopharma 105

Biopharma Medicine Leads Manufacturing 105

European Pharmaceutical Review

MARCH 6, 2024

The advanced laboratory space gives the company internal capability “not only to progress the development of our lead radiopharmaceutical candidates but to provide a state-of-the-art research hub to advance R&D collaborations and identify exciting new pipeline candidates,” Manfred Rüdiger, Chief Executive Officer of Ariceum Therapeutics shared.

Pharmacology 105

Pharmacology Leads Pharmaceutical Patients 105

European Pharmaceutical Review

SEPTEMBER 20, 2023

Conversely, poor analytical characterisation will likely lead to questions from regulators and, without sufficient product and process knowledge, an IND or BLA that is eventually deemed incomplete. Incorrect DNA sequences can also lead to high levels of SVs. While SVs are typically present at less than 0.1

Patients 98

Patients Manufacturing Leads Safety 98

European Pharmaceutical Review

NOVEMBER 13, 2023

Data revealed at the AHA 2023 Scientific Sessions showed that participants who received lepodisiran had lipoprotein(a) levels reduced by the top dose as much as 96 percent within two weeks. The clinical trial enrolled 48 patients in the US and Singapore with a mean age of 47.

Leads 111

Leads Safety Manufacturing Medical 111

PM360

NOVEMBER 21, 2024

Because the signs and symptoms of endogenous hypercortisolism often masquerade as those of other conditions, patients often go undiagnosed for between five and ten years, leading to significantly increased morbidity and mortality.

Marketing 52

Marketing Education Prescription Sales 52

Pharmaceutical Technology

JUNE 7, 2023

Eli Lilly has achieved significant gains in the past quarter, leading to it becoming the most valuable pharmaceutical company in the world, with a market cap of $420bn, surpassing Johnson & Johnson. of patients’ body weight (52lb or 24kg) and greater than 50% of patients taking Mounjaro achieving at least 20% body weight reductions.

Leads 98

Leads Marketing Sales FDA 98

European Pharmaceutical Review

MARCH 26, 2024

.” Moderna reveals optimistic data for influenza-COVID-19 vaccine A promising mRNA vaccine What the clinical data showed Findings from the NextCOVE Phase III pivotal trial showed that mRNA-1283 facilitated a higher immune response in patients against both the Omicron BA.4/BA.5 Moderna’s Spikevax XBB.1.5-adapted

Safety 110

Safety Leads Patients Pharmaceutical 110

Pharmaceutical Technology

FEBRUARY 10, 2023

4DMT had paused enrollment of patients to two of its trials for 4D-310 last month following a significant adverse event where three patients experienced kidney issues; however, these were treated and resolved in a four-week period.

FDA 105

FDA Leads Competition Marketing 105

European Pharmaceutical Review

SEPTEMBER 27, 2023

Results from Small Pharma’s Phase Ib study in selective serotonin reuptake inhibitor (SSRIs) interaction with SPL026, native N, N-dimethyltryptamine (DMT) has revealed that 92 percent of patients gained remission from major depressive disorder ( MDD ). Currently, SSRIs are the standard of care for MDD.

Pharma 105

Pharma Biopharma Patients Leads 105

European Pharmaceutical Review

FEBRUARY 22, 2024

The National Institute for Health and Care Excellence (NICE) has recommended LITFULO ® (ritlecitinib) for treating certain patients with severe alopecia areata. This is “an important milestone” according to Lynn Clay, Specialty Care Lead at Pfizer UK. NICE’s decision was published in its Final Draft Guidance.

Medicine 98

Medicine Leads Healthcare Healthcare 98

European Pharmaceutical Review

MAY 24, 2023

VYJUVEK (beremagene geperpavec-svdt) is authorised for DEB patients six months of age or older. This can lead to extremely fragile skin that blisters and tears with minor friction or trauma. DEB patients suffer from open wounds and can be subject to recurrent skin infections and fibrosis that can cause fusion of fingers and toes.

Food and Drug Administration 105

Food and Drug Administration Medicine FDA Food 105

European Pharmaceutical Review

MAY 1, 2023

In February 2023, results from a Phase III study showed Bristol Myers Squibbs’ Abecma more than tripled progression-free survival for multiple myeloma (MM) patients. The manufacture of cell therapies is a complex operation, as they are produced as personalised therapies for individual patients.

Manufacturing 98

Manufacturing Engineering Networking Patients 98

European Pharmaceutical Review

SEPTEMBER 6, 2023

Bristol Myers Squibb’s first-in-class treatment option is recommended for eligible oHCM patients on the NHS. Bristol Myers Squibb highlighted that oHCM affects approximately 70 percent of patients. What is mavacamten? Mavacamten is an allosteric and reversible cardiac myosin inhibitor. It is administered orally once per day.

Management 97

Management Consulting Marketing Patients 97

Pharmaceutical Technology

APRIL 12, 2023

Pharming Group has conducted the first commercial shipments of oral selective PI3Kδ inhibitor Joenja (leniolisib) to patients diagnosed with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in the US. In March 2023, Joenja secured approval from the US Food and Drug Administration (FDA) to treat the targeted patients.

Food and Drug Administration 59

Food and Drug Administration Patients Food FDA 59